Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Posts Q2 Revenue Growth, Ballooning Net Loss

NEW YORK, July 24 - Ciphergen Biosystems today reported string growth in second-quarter revenue atop increased R&D spending and widened net loss.

 

Revenue for the period ended June 30 surged to $14.3 million from $8.7 million in the year-ago period. Ciphergen attributed the increase to greater sales of its ProteinChip systems and arrays, its automation accessories, and from its BioSepra process proteomics products.

 

R&D spending also saw an increase in the second quarter, to $7 million from $4.7 million in the same period last year.

 

Second-quarter net loss swelled to $15.6 million, or $.56 per share, from $4.7 million, or $.7.3 million per share, year over year. Ciphergen said a contributing factor of the increased loss was $7.3 million in litigation fees as part of a settlement with LumiCyte.

 

As GenomeWeb reported at the end of May, Ciphergen, LumiCyte, and Molecular Analytical Systems settled their lawsuit over a mass-spectrometry technology called SELDI-TOF.

 

Under the terms of the settlement, Ciphergen will pay Molecular Analytical Systems revenue-based royalties of up to $10 million over 10 years. Ciphergen will also issue about 1.25 million shares to LumiCyte and pay the company about $3 million in cash.

 

In return, Ciphergen will gain access to Molecular Analytical's exclusive worldwide patent rights to surface enhanced laser desorption ionization time-of-flight mass spectrometry, or SELDI-TOF-MS.

 

Ciphergen said it had around $28.2 million in cash, cash equivalents, and investments as of June 30.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.